Polyadenylic-polyuridylic acid plus locoregional radiotherapy versus chemotherapy with CMF in operable breast cancer: A 14 year follow-up analysis ofa randomized trial of the Federation Nationale des Centres de Lutte Contrele Cancer (FNCLCC)

Authors
Laplanche, A Alzieu, L Delozier, T Berlie, J Veyret, C Fargeot, P Luboinski, M Lacour, J
Citation
A. Laplanche et al., Polyadenylic-polyuridylic acid plus locoregional radiotherapy versus chemotherapy with CMF in operable breast cancer: A 14 year follow-up analysis ofa randomized trial of the Federation Nationale des Centres de Lutte Contrele Cancer (FNCLCC), BREAST CANC, 64(2), 2000, pp. 189-191
Citations number
4
Categorie Soggetti
Oncology,"Onconogenesis & Cancer Research
Journal title
BREAST CANCER RESEARCH AND TREATMENT
ISSN journal
01676806 → ACNP
Volume
64
Issue
2
Year of publication
2000
Pages
189 - 191
Database
ISI
SICI code
0167-6806(200011)64:2<189:PAPLRV>2.0.ZU;2-9
Abstract
With a median follow-up of 14 years, the combination of polyadenylic-polyur idylic acid plus locoregional radiotherapy (257 patients) has significantly improved disease-free survival (p = 0.03) and significantly reduced the in cidence of metastases (p = 0.04) when compared to CMF alone (260 patients), in women with operable breast cancer. The trial does not, however, permit an appreciation of the respective role of radiotherapy and PolyAU in these results.